Orthocell Ltd (ASX:OCC) has tapped Dr Ravi I Thadhani MD, MPH, an experienced US-based healthcare executive, as an independent non-executive director for the company’s board.
Dr Thadhani has more than 30 years of specialist experience in the US healthcare sector and is a well-regarded executive, medical administrator and researcher whom Orthocell believes is ideally suited to support the next phase of the company’s development.
The company says Dr Thadhani brings a ‘wealth of experience’ as an advisor to the US FDA and consultant to multiple global healthcare companies.
OCC is particularly interested in his extensive experience advancing novel research programs, advising US regulatory pathways and commercialisation of devices and therapeutics.
“Ideally suited to our next phase of growth”
“We are delighted to welcome Dr Thadhani to the Orthocell board,” Othorcell managing director Paul Anderson said.
“Dr Thadhani is a globally recognised healthcare executive, physician and researcher with a passion for translating medical research into market-leading products and delivering the highest quality patient care.
“Dr Thadhani is a dynamic and collaborative leader with a depth of knowledge, expertise and US healthcare network that is ideally suited to our next phase of growth at Orthocell.
“I am thrilled to be working alongside Dr Thadhani to advance the commercialisation of our unique medical devices and cellular therapies.”
Dr Thadhani has served on multiple US FDA advisory committees in the musculoskeletal, cardiovascular and renal sectors providing expert guidance to the FDA and companies regarding the regulatory requirements for approval of medical devices and therapeutics.
Read: Orthocell secures inclusion for Remplir™ on the prostheses list
He has also co-authored more than 300 scientific publications, including articles in top medical journals, such as the New England Journal of Medicine, the Lancet and the Journal of the American Medical Association.
Read: Orthocell data demonstrates OrthoATI rotator cuff treatment more effective than steroid injections
“I am very excited to be joining the leadership team at Orthocell at this pivotal stage in the company’s development,” Dr Thadhani said.
“The company is in a strong position and has a unique set of complementary products and pipeline opportunities that have the potential to deliver higher quality and more cost-effective solutions for both physicians and patients.
“I look forward to assisting the team to advance the commercialisation of these significant opportunities.”